A study on fatty liver in patients admitted to medical wards in tertiary hospital
Keywords:Alcoholic fatty liver disease, Cardiovascular disease, Hepatocellular carcinoma, Metabolic syndrome, Non-alcoholic fatty liver disease
Background: Fatty liver is a common clinical condition seen in medical wards. It can be either alcoholic fatty liver disease or non-alcoholic fatty liver disease. It is an iceberg phenomenon which can be associated with metabolic syndrome, cardiovascular disease and hepatocellular carcinoma. The aim of the present study is to observe and analyse the prevalence of fatty liver diseases in general population admitted to general wards in department of general medicine and to help in the timely prevention of associated risk factors and complications
Methods: It is a prospective cross-sectional study conducted in Narayana medical college and hospital a tertiary care hospital for a period of 6 months from November 2017 to May 2018 and includes a total of 250 patients. Patients were routinely screened with ultrasound abdomen and those having fatty liver changes were included in this study and their clinical and biochemical parameters were examined.
Results: Out of the 250 patients admitted to medical wards during the study period, 70 patients (28%) had fatty liver. Out of these, 23 (34%) were males and 47 (67%) were females, alcoholics were 9 (12.8%) and non-alcoholics were (87.2%), 35 (50%) were diabetics, 11 (15.7%) had CAD (coronary artery disease), 29 (41.4%) were obese with BMI >30 and 26 (37.1%) were hypertensive.
Conclusions: Fatty liver is a common incidental finding in ultrasound abdomen in patients admitted to medical wards and when neglected, which when given importance and with proper intervention and life style modifications can prevent metabolic syndrome, cardiovascular disease and hepatocellular carcinoma.
Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, et al. The clinicopathological profile of Indian patients with non-alcoholic fatty liver disease (NAFLD) is different from that in the West. Digestive Dis Sci. 2007 Sep 1;52(9):2368-74.
Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Internal Med. 2000 Jan 18;132(2):112-7.
Bi L, Jiang Z, Zhou J. The role of lipin-1 in the pathogenesis of alcoholic fatty liver. Alcohol Alcoholism. 2015 Jan 16;50(2):146-51.
Yin H, Hu M, Liang X, Ajmo JM, Li X, Bataller R, et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver. Gastroenterol. 2014 Mar 1;146(3):801-11.
White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012 Dec 1;10(12):1342-59.
Roychowdhury S, Selvakumar P, Cresci G. The role of the gut microbiome in nonalcoholic fatty liver disease. Med Sci. 2018 Jun 5;6(2):47.
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Practice Res Clin Gastroenterol. 2014 Aug 1;28(4):637-53.
Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nature Reviews Gastroenterol Hepatol. 2013 Jun;10(6):330.
Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837-58.
Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatol. 2003 Jun;37(6):1286-92.
Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011 Dec 1;43(8):617-49.
Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?. World J Gastroenterol. 2014 Jul 21;20(27):9072.
Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. 2018;91(2):147-50.
Cicero A, Colletti A, Bellentani S. Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): the available clinical evidence. Nutrients. 2018 Aug 23;10(9):1153.
Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014 Sep 28;20(36):12956-80.
Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surgery Nutrition. 2015 Apr;4(2):101.
Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA Journal. 2014 Dec 1;5(1):21.
Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018 Aug 27;10(8):530.